17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients after First-Line Treatment with Immunochemotherapy: A Retrospective Study of 151 Patients David Alonso , Almudena Navarro , Elena Alejo , Maria Garcia , Jose Antonio Queizan , Almudena Cabero , Maria Eugenia Alonso , Ana Garcia-Bacelar , Julio Davila , Jorge Labrador , Silvia Fernandez , Beatriz Albarran , Carlos Aguilar , Emilia Pardal , Erick De Cabo , Maria Jesus Penarrubia , Borja Cidoncha , Gerardo Martinez , Teresa Villaescusa , Jose Maria Navarro , Sandra Patricia Gomez , Carlos Puerta , Pablo Garcia-Jaen , Evelyn Gabriela Zapata , Diego Clavo , Rafael Jose Malaver , Cristina Teresa Fuentes , Adolfo Fernandez , Carmen Santos , Alejandro Martin , Miguel Alcoceba , Carmen Norma Gutierrez CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
Key words
ABCL, diffuse large B-cell lymphoma (DLBCL), 17p deletion [del(17p)]
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
